Our results in the present study suggest that the PI3K-AKT-mTOR pathway is crucial in the adipocyte-mediated breast cancer progression and that dual inhibitors targeting PI3K and mTOR such as BEZ235 could be a good option to inhibit the obesity-breast cancer link. Here, AKT1 is linked to obesity due to melanocortin 4 receptor deficiency.